The decline of BCR-ABL/GUS ratio in CML patients treated upfront with nilotinib shows a rapid descent during the first trimester, and the responses are similar to those achieved with ABL as control
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Fecha de publicación
2014Título de revista
Haematologica
Tipo de contenido
Publicación de congreso
![](/xmlui/themes/Mirage2//images/final_lines.png)